ABSTRACT
Bisphenol S (BPS), an analogue of the controversial bisphenol A (BPA) that is found in epoxy resins and plastics, is a potential endocrine-disrupting chemical that can mimic endogenous hormone signaling. However, little is known about the behavioral or immunologic effects of BPS. The purpose of this study was to examine the impact of diets in BPS-treated mice in relation to hyperglycemia, development of type 1 diabetes, immunomodulation, and behavioral changes. Adult male and female nonobese diabetic excluded flora (NODEF) mice were exposed to environmentally relevant doses of BPS (VH, 30, or 300 µg/kg BW) and fed either a soy-based diet, a phytoestrogen-free diet, or a Western diet. NODEF male mice fed a soy-based diet exhibited a decreased curiosity/desire to explore, and possibly increased anxiety-like behavior and decreased short-term memory when exposed to BPS (300 µg/kg BW). In addition, these mice had significant increases in non-fasting blood glucose levels along with increased insulin sensitivity, impaired glucose tolerance, resistance to fasting and proinflammation. Although BPS had little effect on the glucose parameters in NODEF male mice fed a Western diet, there were decreases in %CD24+CD5+ and %B220+CD40L-cell populations and increases in distance traveled during the novel object test, suggesting hyperactivity. NODEF females fed a phytoestrogen-free diet exhibited slight decreases in time spent immobile during the tail suspension test in both the 30 and 300 µg/kg BW dose groups along with increases in %CD4+CD8+ and %Mac3+CD45R+ cell populations, signifying increased hyperactivity and anxiety-like behavior. In conclusion, BPS-exposed NODEF mice exhibited sex and diet-related changes in hyperglycemia, behaviors and immune endpoints.
Subject(s)
Diet, Western/adverse effects , Hyperglycemia/metabolism , Hyperkinesis/metabolism , Phenols/toxicity , Soy Foods/adverse effects , Sulfones/toxicity , Animals , Blood Glucose/metabolism , Diet, Western/psychology , Endocrine Disruptors/toxicity , Female , Hyperglycemia/chemically induced , Hyperglycemia/psychology , Hyperkinesis/chemically induced , Hyperkinesis/psychology , Male , Mice , Mice, Inbred NOD , Phytoestrogens/administration & dosage , Phytoestrogens/adverse effectsABSTRACT
Parkinson's disease is characterized by both hypokinetic and hyperkinetic symptoms. While increased subthalamic burst discharges have a direct causal relationship with the hypokinetic manifestations (e.g., rigidity and bradykinesia), the origin of the hyperkinetic symptoms (e.g., resting tremor and propulsive gait) has remained obscure. Neuronal burst discharges are presumed to be autonomous or less responsive to synaptic input, thereby interrupting the information flow. We, however, demonstrate that subthalamic burst discharges are dependent on cortical glutamatergic synaptic input, which is enhanced by A-type K+ channel inhibition. Excessive top-down-triggered subthalamic burst discharges then drive highly correlative activities bottom-up in the motor cortices and skeletal muscles. This leads to hyperkinetic behaviors such as tremors, which are effectively ameliorated by inhibition of cortico-subthalamic AMPAergic synaptic transmission. We conclude that subthalamic burst discharges play an imperative role in cortico-subcortical information relay, and they critically contribute to the pathogenesis of both hypokinetic and hyperkinetic parkinsonian symptoms.
Subject(s)
Globus Pallidus/physiopathology , Hyperkinesis/physiopathology , Motor Cortex/physiopathology , Parkinson Disease, Secondary/physiopathology , Subthalamic Nucleus/physiopathology , Tremor/physiopathology , 4-Aminopyridine/pharmacology , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Female , Globus Pallidus/drug effects , Globus Pallidus/metabolism , Glutamic Acid/metabolism , Glutamic Acid/pharmacology , Humans , Hyperkinesis/metabolism , Male , Membrane Potentials/drug effects , Mice, Inbred C57BL , Motor Cortex/drug effects , Motor Cortex/metabolism , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Muscle, Skeletal/physiopathology , Optogenetics/methods , Parkinson Disease, Secondary/metabolism , Rats , Rats, Wistar , Subthalamic Nucleus/drug effects , Subthalamic Nucleus/metabolism , Synapses/drug effects , Synapses/metabolism , Synapses/pathology , Synaptic Transmission , Tremor/metabolism , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacologyABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Essential hypertension is a prevalence chronic cardiovascular disease, which is treated by traditional Chinese medicine (TCM) in China. Metabolomics approach has achieved more attention in pharmacology studies of natural products. Tianma Gouteng Decoction (TGD) is effective for the therapeutic of hypertension in China. We aimed to investigate antihypertension effect of TGD on spontaneous hypertension rat (SHR) with live-Yang hyperactivity hypertension (Gan Yang Shang Kang, GYSK) and explore the mechanism by metabolomics method. MATERIALS AND METHODS: After establishing the GYSK-SHR model by giving aconite decoction, rats were randomly divided into four groups including model group, TGD qd group (66.88 mg/kg, once a day), TGD bid group (33.44 mg/kg, twice a day), TGD tid group (22.29 mg/kg, three times a day). Blood pressure (BP) and indexes of renin-angiotensin-aldosterone system (RAAS system) were measured. Metabolic profiling of rat plasma samples was performed by UPLC-Q-TOF/MS, which was analyzed with principal component analysis (PCA) and partial least-squares-discriminate analysis (PLS-DA) to explore the relationship between metabolic pathways and hypertension. RESULTS: To better explain the role of TGD on hypertension, we detected three different frequencies of TGD treatment with equal dosage. TGD reduced the BP in GYSH-SHR model and regulated the serum levels of NE, Ang II, ET, 5-HT, CRP, RENIN and ALD especially at TGD bid group. By UPLC-Q-TOF/MS analysis, we found 47 potential biomarkers in GYSK-SHR rats from the plasma metabolites, among which 15 biomarkers were regulated by TGD. Consisted with the antihypertension activity, TGD bid group showed the significantly moderating effect on the regulating biomarkers. CONCLUSIONS: TGD exhibited the antihypertensive activity at the frequency of administration twice a day, which had the association with RAAS system and mediated 15 biomarkers by regulating metabolisms of glycerol phospholipid, sphingomyelin, energy and amino acid.
Subject(s)
Antihypertensive Agents/pharmacology , Drugs, Chinese Herbal/pharmacology , Hypertension/metabolism , Aldosterone/blood , Angiotensin II/blood , Animals , Antihypertensive Agents/therapeutic use , Biomarkers/blood , C-Reactive Protein/analysis , Drugs, Chinese Herbal/therapeutic use , Endothelins/blood , Hyperkinesis/blood , Hyperkinesis/drug therapy , Hyperkinesis/metabolism , Hypertension/blood , Hypertension/drug therapy , Male , Metabolomics , Norepinephrine/blood , Rats, Inbred SHR , Rats, Sprague-Dawley , SyndromeABSTRACT
RATIONALE: Altered glutamate NMDA receptor function is implicated in schizophrenia, and gender differences have been demonstrated in this illness. OBJECTIVES: This study aimed to investigate the interaction of gonadal hormones with NMDA receptor-mediated locomotor hyperactivity and PPI disruption in mice. RESULTS: The effect of 0.25 mg/kg of MK-801 on locomotor activity was greater in male mice than in female mice. Gonadectomy (by surgical castration) significantly reduced MK-801-induced hyperlocomotion in male mice, but no effect of gonadectomy was seen in female mice or on amphetamine-induced locomotor hyperactivity. The effect of MK-801 on prepulse inhibition of startle (PPI) was similar in intact and castrated male mice and in ovariectomized (OVX) female mice. In contrast, there was no effect of MK-801 on PPI in intact female mice. Forebrain NMDA receptor density, as measured with [3H]MK-801 autoradiography, was significantly higher in male than in female mice but was not significantly altered by either castration or OVX. CONCLUSIONS: These results suggest that male sex hormones enhance the effect of NMDA receptor blockade on psychosis-like behaviour. This interaction was not seen in female mice and was independent of NMDA receptor density in the forebrain. Male sex hormones may be involved in psychosis by an interaction with NMDA receptor hypofunction.
Subject(s)
Gonadal Steroid Hormones/metabolism , Hyperkinesis/chemically induced , Hyperkinesis/metabolism , Receptors, N-Methyl-D-Aspartate/physiology , Acoustic Stimulation/methods , Animals , Brain/drug effects , Brain/metabolism , Dizocilpine Maleate/toxicity , Female , Male , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Motor Activity/physiology , Orchiectomy , Ovariectomy , Prepulse Inhibition/drug effects , Prepulse Inhibition/physiology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Reflex, Startle/drug effects , Reflex, Startle/physiologyABSTRACT
Studies have shown that oxidative stress is involved in the pathophysiology of bipolar disorder (BD). It is suggested that omega-3 (ω3) fatty acids are fundamental to maintaining the functional integrity of the central nervous system. The animal model used in this study displayed fenproporex-induced hyperactivity, a symptom similar to manic BD. Our results showed that the administration of fenproporex, in the prevent treatment protocol, increased lipid peroxidation in the prefrontal cortex (143%), hippocampus (58%) and striatum (181%), and ω3 fatty acids alone prevented this change in the prefrontal cortex and hippocampus, whereas the co-administration of ω3 fatty acids with VPA prevented the lipoperoxidation in all analyzed brain areas, and the co-administration of ω3 fatty acids with Li prevented this increase only in the prefrontal cortex and striatum. Moreover, superoxide dismutase (SOD) activity was decreased in the striatum (54%) in the prevention treatment, and the administration of ω3 fatty acids alone or in combination with Li and VPA partially prevented this inhibition. On the other hand, in the reversal treatment protocol, the administration of fenproporex increased carbonyl content in the prefrontal cortex (25%), hippocampus (114%) and striatum (91%), and in prefrontal coxter the administration of ω3 fatty acids alone or in combination with Li and VPA reversed this change, whereas in the hippocampus and striatum only ω3 fatty acids alone or in combination with VPA reversed this effect. Additionally, the administration of fenproporex resulted in a marked increase of TBARS in the hippocampus and striatum, and ω3 fatty acids alone or in combination with Li and VPA reversed this change. Finally, fenproporex administration decreased SOD activity in the prefrontal cortex (85%), hippocampus (52%) and striatum (76%), and the ω3 fatty acids in combination with VPA reversed this change in the prefrontal cortex and striatum, while the co-administration of ω3 fatty acids with Li reversed this inhibition in the hippocampus and striatum. In conclusion, our results support other studies showing the importance of ω3 fatty acids in the brain and the potential for these fatty acids to aid in the treatment of BD.
Subject(s)
Amphetamines/toxicity , Antimanic Agents/therapeutic use , Appetite Depressants/toxicity , Behavior, Animal/drug effects , Fatty Acids, Omega-3/therapeutic use , Hyperkinesis/psychology , Oxidative Stress/drug effects , Animals , Brain Chemistry/drug effects , Hyperkinesis/chemically induced , Hyperkinesis/metabolism , Lipid Peroxidation/drug effects , Lithium Carbonate/therapeutic use , Male , Protein Carbonylation/drug effects , Rats , Rats, Wistar , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism , Valproic Acid/therapeutic useABSTRACT
Recent evidence suggests that interneurons are involved in the pathophysiology of Huntington Disease (HD). Abnormalities in the function of interneurons expressing the calcium buffer parvalbumin (PV) have been observed in multiple mouse models of HD, although it is not clear how PV-positive interneuron dysfunction contributes to behavioral and synaptic deficits. Here, we use the cre-lox system to drive expression of mutant huntingtin (mthtt) in parvalbumin (PV)-positive neurons and find that mutant mice exhibit diffuse mthtt immunoreactivity in PV-rich areas at 10months of age and mthtt aggregates in PV-positive processes at 24months of age. At midlife, mutant mice are hyperactive and display impaired GABA release in the motor cortex, characterized by reduced miniature inhibitory events and severely blunted responses to gamma frequency stimulation, without a loss of PV-positive interneurons. In contrast, 24month-old mutant mice show normalized behavior and responses to gamma frequency stimulation, possibly due to compensatory changes in pyramidal neurons or the formation of inclusions with age. These data indicate that mthtt expression in PV-positive neurons is sufficient to drive a hyperactive phenotype and suggest that mthtt-mediated dysfunction in PV-positive neuronal populations could be a key factor in the hyperkinetic behavior observed in HD. Further clarification of the roles for specific PV-positive populations in this phenotype is warranted to definitively identify cellular targets for intervention.
Subject(s)
Hyperkinesis/metabolism , Inhibitory Postsynaptic Potentials , Interneurons/physiology , Motor Cortex/physiopathology , Nerve Tissue Proteins/metabolism , Nuclear Proteins/metabolism , Parvalbumins/metabolism , Age Factors , Animals , Brain/metabolism , Female , Huntingtin Protein , Hyperkinesis/physiopathology , Male , Mice , Mice, Transgenic , Mutation , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , gamma-Aminobutyric Acid/metabolismABSTRACT
Impaired transmission through glutamatergic circuits has been postulated to play a role in the underlying pathophysiology of schizophrenia. Furthermore, inhibition of the N-methyl-d-aspartate (NMDA) subtype of ionotropic glutamate receptors (NMDAR) induces a syndrome that recapitulates many of the symptoms observed in patients with schizophrenia. Selective activation of metabotropic glutamate receptor subtype 5 (mGlu5) may provide a novel therapeutic approach for treatment of symptoms associated with schizophrenia through facilitation of transmission through central glutamatergic circuits. Here, we describe the characterization of two novel N-aryl piperazine mGlu5 positive allosteric modulators (PAMs): 2-(4-(2-(benzyloxy)acetyl)piperazin-1-yl)benzonitrile (VU0364289) and 1-(4-(2,4-difluorophenyl)piperazin-1-yl)-2-((4-fluorobenzyl)oxy)ethanone (DPFE). VU0364289 and DPFE induced robust leftward shifts in the glutamate concentration-response curves for Ca(2+) mobilization and extracellular signal-regulated kinases 1 and 2 phosphorylation. Both PAMs displayed micromolar affinity for the common mGlu5 allosteric binding site and high selectivity for mGlu5. VU0364289 and DPFE possessed suitable pharmacokinetic properties for dosing in vivo and produced robust dose-related effects in reversing amphetamine-induced hyperlocomotion, a preclinical model predictive of antipsychotic-like activity. In addition, DPFE enhanced acquisition of contextual fear conditioning in rats and reversed behavioral deficits in a mouse model of NMDAR hypofunction. In contrast, DPFE had no effect on reversing apomorphine-induced disruptions of prepulse inhibition of the acoustic startle reflex. These mGlu5 PAMs also increased monoamine levels in the prefrontal cortex, enhanced performance in a hippocampal-mediated memory task, and elicited changes in electroencephalogram dynamics commensurate with procognitive effects. Collectively, these data support and extend the role for the development of novel mGlu5 PAMs for the treatment of psychosis and cognitive deficits observed in individuals with schizophrenia.
Subject(s)
Antipsychotic Agents/pharmacology , Hyperkinesis/drug therapy , Memory, Short-Term/drug effects , Nootropic Agents/pharmacology , Piperazines/pharmacology , Receptor, Metabotropic Glutamate 5/agonists , Receptors, N-Methyl-D-Aspartate/metabolism , Allosteric Regulation , Animals , Antipsychotic Agents/chemistry , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/therapeutic use , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , HEK293 Cells , Humans , Hyperkinesis/metabolism , Hyperkinesis/psychology , Male , Maze Learning/drug effects , Mice , Mice, Knockout , Motor Activity/drug effects , Nootropic Agents/chemistry , Nootropic Agents/pharmacokinetics , Nootropic Agents/therapeutic use , Piperazines/chemistry , Piperazines/pharmacokinetics , Piperazines/therapeutic use , Rats , Rats, Sprague-Dawley , Receptor, Metabotropic Glutamate 5/genetics , Receptors, N-Methyl-D-Aspartate/genetics , Schizophrenia/drug therapy , Schizophrenia/metabolism , TransfectionABSTRACT
Bradykinesia is one of the major clinical symptoms of Parkinson`s disease (PD) for which treatment is sought. In most mouse models of PD, decreased locomotor activity can be reflected in an open field behavioral test. Therefore the open field test provides a useful tool to study the clinic symptoms of PD patients. Our previous work demonstrated that 100 Hz electro-acupuncture (EA) stimulation at ZUSANLI and SANYINJIAO protected the dopaminergic nigrostriatal system of C57BL/6 mice from MPTP toxicity, indicating that acupuncture might be an effective therapy for PD sufferers. In the present study, we investigated the effects of 100 Hz EA stimulation on the spontaneous locomotor activity in MPTP injured mice. Here we found that, in MPTP treated mice, the total movements significantly decreased and the movement time, velocity and distance dramatically increased, although the dopaminergic nigrostriatal system was devastated, revealed by immunohistochemistry and HPLC-ECD. After 12 sessions of 100 Hz EA stimulation, the total movements elevated and the movement time, velocity and distance decreased, in MPTP mice. 100 Hz EA increased striatal dopamine content in MPTP mice by 35.9%, but decreased its striatal dopamine turnover. We assumed that the injury of other regions in the brain, such as the A11 group in diencephalon, might be involved in the hypermotility in MPTP mice. The effects of 100 Hz EA on spontaneous locomotor activity in MPTP mice might not relate with the striatal dopamine, but with its neuroprotective and regulatory effects on motor circuits in the brain. Our study suggests that EA might be a promising treatment for neurological disorders including PD.
Subject(s)
Electroacupuncture , Hyperkinesis/physiopathology , Hyperkinesis/therapy , MPTP Poisoning/physiopathology , MPTP Poisoning/therapy , Motor Activity/drug effects , Animals , Behavior, Animal/drug effects , Dopamine/metabolism , Hyperkinesis/chemically induced , Hyperkinesis/metabolism , MPTP Poisoning/metabolism , Male , Mice , Mice, Inbred C57BL , Neostriatum/drug effects , Neostriatum/metabolism , Neostriatum/physiopathologyABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Rosemary, Rosmarinus ofï¬cinalis L., has several therapeutic applications in folk medicine for the treatment of a wide range of diseases, including depression. AIM OF THE STUDY: To evaluate the ability of Rosmarinus ofï¬cinalis hydroalcoholic extract (ROHE), as compared to the positive control fluoxetine, to reverse behavioral (hyperactivity, anhedonic behavior and learning deficit in water maze) and biochemical alterations (serum glucose level and acetylcholinesterase, AChE, activity) induced by an animal model of depression, the olfactory bulbectomy (OB) in mice. MATERIALS AND METHODS: Locomotor and exploratory behavior was assessed in the open-field, novel object and novel cage tests, anhedonic behavior was assessed in the splash test; cognitive deficits were evaluated in the water maze task. For the first set of experiments, ROHE (10-300 mg/kg) or fluoxetine (10mg/kg) was administered once daily (p.o.) for 14 days after OB and the behavioral tests were performed. For the second set of experiments, serum glucose and hippocampal and cerebrocortical AChE activity were determined in OB and SHAM-operated mice treated orally with ROHE (10mg/kg), fluoxetine (10mg/kg) or vehicle. RESULTS: ROHE (10-300 mg/kg), similar to fluoxetine, reversed OB-induced hyperactivity, increased exploratory and anhedonic behavior. OB needed significantly more trials in the training session to acquire the spatial information, but they displayed a similar profile to that of SHAM mice in the test session (24h later), demonstrating a selective deficit in spatial learning, which was not reversed by ROHE or fluoxetine. A reduced serum glucose level and an increased hippocampal AChE activity were observed in bulbectomized mice; only the latter effect was reversed by fluoxetine, while both effects were reversed by ROHE. CONCLUSIONS: ROHE exerted an antidepressant-like effect in bulbectomized mice and was able to abolish AchE alterations and hypoglycemia, but not spatial learning deficit induced by OB. Overall, results suggest the potential of Rosmarinus officinalis for the treatment of depression, validating the traditional use of this plant.
Subject(s)
Behavior, Animal/drug effects , Depression/drug therapy , Learning Disabilities/metabolism , Learning/drug effects , Phytotherapy , Plant Extracts/therapeutic use , Rosmarinus , Acetylcholinesterase/metabolism , Animals , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Blood Glucose/metabolism , Depression/complications , Depression/metabolism , Exploratory Behavior/drug effects , Female , Fluoxetine/pharmacology , Fluoxetine/therapeutic use , Hippocampus/drug effects , Hippocampus/metabolism , Hyperkinesis/drug therapy , Hyperkinesis/etiology , Hyperkinesis/metabolism , Hypoglycemia/drug therapy , Learning Disabilities/drug therapy , Learning Disabilities/etiology , Mice , Mice, Inbred Strains , Olfactory Bulb/surgery , Plant Extracts/pharmacologyABSTRACT
This study was undertaken to ascertain the antipsychotic properties of Rauwolfia tetraphylla L. leaves and to isolate and characterize the antipsychotic constituents. Among the MeOH extract and some alkaloidal fractions at different pHs, the alkaloidal CHCl(3) fraction at pH-9 (2C) showed the highest antipsychotic activity against dopaminergic (DA-D(2)) and serotonergic (5-HT(2A)) receptors in-vitro and amphetamine induced hyperactive mouse model in-vivo. The activity guided isolation of CHCl(3) fraction (2C) afforded six indole alkaloids: 10-methoxytetrahydroalstonine (1), isoreserpiline (2), an isomeric mixture of 11-demethoxyreserpiline (3) and 10-demethoxyreserpiline (4), α-yohimbine (5) and reserpiline (6). Given orally, alkaloids 3-6 showed significant antipsychotic activity in a dose dependent manner. None of the extract, alkaloidal fractions or alkaloids showed any extra pyramidal symptoms at the tested doses. It was also observed that MeOH extract was behaving similar to other clinically used novel atypical antipsychotics in having 5-HT(2A) occupancy greater than the DA-D(2) receptor at the tested doses. Further toxicity and safety evaluation studies of MeOH extracts of R. tetraphylla leaves at different doses (10, 100, 300 and 2000 mg/kg) on female Swiss albino mice showed that MeOH extract is non toxic. The isolated alkaloids, 3-6 could serve as a promising lead structure for drug development of treating psychotic conditions in human.
Subject(s)
Antipsychotic Agents/therapeutic use , Hyperkinesis/drug therapy , Indole Alkaloids/therapeutic use , Phytotherapy , Plant Extracts/therapeutic use , Rauwolfia/chemistry , Receptors, Biogenic Amine/metabolism , Amphetamine , Animals , Antipsychotic Agents/isolation & purification , Antipsychotic Agents/pharmacology , Dose-Response Relationship, Drug , Female , Hydrogen-Ion Concentration , Hyperkinesis/chemically induced , Hyperkinesis/metabolism , Indole Alkaloids/chemistry , Indole Alkaloids/pharmacology , Mice , Mice, Inbred Strains , Neurotransmitter Agents/isolation & purification , Neurotransmitter Agents/pharmacology , Neurotransmitter Agents/therapeutic use , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Receptors, Dopamine/metabolism , Receptors, Serotonin/metabolismABSTRACT
Many neurological and psychiatric disorders are treated with dopamine modulators. Studies in mice may reveal genetic factors underlying those disorders or responsiveness to various treatments, and species and strain differences both complicate the use of mice and provide valuable tools. We evaluated psychomotor effects of the dopamine D1-like agonist R-6-Br-APB and the dopamine D2-like agonist quinelorane using a locomotor activity procedure in 15 mouse strains (inbred 129S1/SvImJ, 129S6/SvEvTac, 129X1/SvJ, A/J, BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, CAST/EiJ, DBA/2J, FVB/NJ, SJL/J, SPRET/EiJ, outbred Swiss Webster, and CD-1) and Sprague-Dawley rats, using groups of both females and males. Both D1 and D2 stimulation produced hyperactivity in the rats, and surprisingly, only two mouse strains were similar in that regard (C3H/HeJ, SPRET/EiJ). In contrast, the majority of mouse strains exhibited hyperactivity only with D1 stimulation, whereas D2 stimulation had no effect or decreased activity. BALB substrains, A/J and FVB/NJ mice showed only decreased activity after either D1 or D2 stimulation. CAST/EiJ mice exhibited hyperactivity exclusively with D2 stimulation. Sex differences were observed but no systematic trend emerged: For example, of the five strains in which a main factor of sex was identified for the stimulant effects of the D1 agonist, responsiveness was greatest in females in three of those strains and in males in two of those strains. These results should aid in the selection of mouse strains for future studies in which D1 or D2 responsiveness is a necessary consideration in the experimental design.
Subject(s)
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/analogs & derivatives , Central Nervous System Stimulants/pharmacology , Dopamine Agonists/pharmacology , Dopamine/metabolism , Hyperkinesis/chemically induced , Motor Activity/drug effects , Quinolines/pharmacology , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/metabolism , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology , Animals , Central Nervous System Stimulants/metabolism , Dopamine Agonists/metabolism , Drug Evaluation, Preclinical , Female , Hyperkinesis/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Inbred Strains , Models, Animal , Rats , Rats, Sprague-Dawley , Sex Factors , Species SpecificityABSTRACT
BACKGROUND AND PURPOSE: An important role of GABAergic neurotransmission in schizophrenia was proposed a long time ago, but there is limited data to support this hypothesis. In the present study we decided to investigate GABA(B) receptor ligands in animal models predictive for the antipsychotic activity of drugs. The GABA(B) receptor antagonists CGP51176 and CGP36742, agonist CGP44532 and positive allosteric modulator GS39783 were studied. EXPERIMENTAL APPROACH: The effects of all ligands were investigated in MK-801- and amphetamine-induced hyperactivity tests. The anti-hallucinogenic-like effect of the compounds was screened in the model of head twitches induced by (±)1-(2.5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Furthermore, the effect of GS39783 and CGP44532 on DOI-induced frequency of spontaneous excitatory postsynaptic currents (EPSCs) in slices from mouse brain frontal cortices was investigated. The anti-cataleptic properties of the compounds were also assessed. KEY RESULTS: The GABA(B) receptor activators CGP44532 and GS39783 exhibited antipsychotic-like effects both in the MK-801- and amphetamine-induced hyperactivity tests, as well as in the head-twitch model in mice. Such effects were not observed for the GABA(B) receptor antagonists. DOI-induced increased frequency of spontaneous EPSCs was also decreased by the compounds. Moreover, CGP44532 and GS39783 inhibited haloperidol-induced catalepsy and EPSCs. CONCLUSION AND IMPLICATIONS: These data suggest that selective GABA(B) receptor activators may be useful in the treatment of psychosis.
Subject(s)
Behavior, Animal/drug effects , Cyclopentanes/therapeutic use , GABA-B Receptor Agonists/therapeutic use , Phosphinic Acids/therapeutic use , Psychoses, Substance-Induced/drug therapy , Pyrimidines/therapeutic use , Receptors, GABA-B/metabolism , gamma-Aminobutyric Acid/analogs & derivatives , Animals , Catalepsy/chemically induced , Cyclopentanes/administration & dosage , Cyclopentanes/adverse effects , Disease Models, Animal , Dose-Response Relationship, Drug , Excitatory Postsynaptic Potentials/drug effects , Frontal Lobe/drug effects , Frontal Lobe/metabolism , Frontal Lobe/physiopathology , GABA-B Receptor Agonists/administration & dosage , GABA-B Receptor Agonists/adverse effects , GABA-B Receptor Antagonists/pharmacology , Hyperkinesis/drug therapy , Hyperkinesis/metabolism , Hyperkinesis/psychology , Male , Mice , Motor Activity/drug effects , Phosphinic Acids/administration & dosage , Phosphinic Acids/adverse effects , Psychoses, Substance-Induced/metabolism , Psychoses, Substance-Induced/psychology , Pyrimidines/administration & dosage , Pyrimidines/adverse effects , Syndrome , gamma-Aminobutyric Acid/administration & dosage , gamma-Aminobutyric Acid/adverse effects , gamma-Aminobutyric Acid/therapeutic useABSTRACT
Aripiprazole is an atypical antipsychotic that acts as a partial agonist at the dopamine D(2) receptor. It has been mainly investigated in dopamine-based models of schizophrenia, while its effects on glutamate-based paradigms have remained to be further characterized. Due to its unique mechanism of action, aripiprazole has also been considered as a replacement medication for psychostimulant abuse. Thus, in the present study we tested the hypothesis that aripiprazole would prevent the motor hyperactivity induced by psychostimulant and psychotomimetic drugs that act either by dopaminergic or glutamatergic mechanisms. Male Swiss mice received injections of aripiprazole (0.1-1 mg/kg) followed by drugs that enhance the dopamine-mediated neurotransmission, amphetamine (3 mg/kg) or cocaine (5 mg/kg), or by glutamate NMDA-receptor antagonists, ketamine (60 mg/kg) or MK-801 (0.4 mg/kg). Independent groups also received aripiprazole (0.1-1 mg/kg) or haloperidol (0.5 mg/kg) and were tested for catalepsy. All doses of aripiprazole were effective in preventing the motor stimulant effects of amphetamine and cocaine. Moreover, the higher dose also prevented the effects of ketamine and MK-801. The present study reports the effects of aripiprazole in dopaminergic and glutamatergic models predictive of antipsychotic activity, suggesting that both may be useful for screening novel partial agonists with antipsychotic activity. It also shows that aripiprazole may prevent the acute effects of psychostimulant drugs without significant motor impairment.
Subject(s)
Antipsychotic Agents/pharmacology , Central Nervous System Stimulants/toxicity , Excitatory Amino Acid Antagonists/toxicity , Hyperkinesis/prevention & control , Motor Activity/drug effects , Piperazines/pharmacology , Quinolones/pharmacology , Amphetamine/toxicity , Animals , Antipsychotic Agents/toxicity , Aripiprazole , Catalepsy/chemically induced , Cocaine/toxicity , Dizocilpine Maleate/toxicity , Dopamine/metabolism , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Drug Partial Agonism , Glutamine/metabolism , Haloperidol/pharmacology , Hyperkinesis/chemically induced , Hyperkinesis/metabolism , Hyperkinesis/physiopathology , Ketamine/toxicity , Locomotion/drug effects , Male , Mice , Piperazines/toxicity , Quinolones/toxicity , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/metabolism , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolism , Time FactorsABSTRACT
Inattention, hyperactivity and impulsiveness are the main symptoms of the heterogeneous attention-deficit/hyperactivity disorder (ADHD). It has been suggested that ADHD is associated with an imbalance in polyunsaturated fatty acid (PUFA) composition, with abnormal low levels of the main n-3 PUFA, DHA (22: 6n-3). DHA is highly accumulated in nervous tissue membranes and is implicated in neural function. Animal studies have shown that diet-induced lack of DHA in the brain leads to alterations in cognitive processes, but the relationship between DHA and hyperactivity is unclear. We examined the membrane phospholipid fatty acid profile in frontal cortex of rats characterized for attention, impulsiveness and motricity in various environmental contexts to determine the relationship between brain PUFA composition and the symptoms of ADHD. The amounts of n-3 PUFA in the PE were significantly correlated with nocturnal locomotor activity and the locomotor response to novelty: hyperactive individuals had less n-3 PUFA than hypoactive ones. We conclude that spontaneous hyperactivity in rats is the symptom of ADHD that best predicts the n-3 PUFA content of the frontal cortex. This differential model in rats should help to better understand the role of PUFA in several psychopathologies in which PUFA composition is modified.
Subject(s)
Fatty Acids, Omega-3/metabolism , Frontal Lobe/metabolism , Hyperkinesis/metabolism , Hyperkinesis/pathology , Animals , Attention/physiology , Behavior, Animal , Choice Behavior/physiology , Disease Models, Animal , Docosahexaenoic Acids/metabolism , Impulsive Behavior/physiopathology , Male , Motor Activity/physiology , Rats , Rats, Sprague-Dawley , Reaction Time/physiology , Statistics as TopicABSTRACT
BACKGROUND: Basic fibroblast growth factor (FGF2) plays a crucial role during the development of the cerebral cortex. Mice with a knockout of the FGF2 gene have a reduced number of glutamatergic neurons within the deep layers of the cerebral cortex. METHODS: We used molecular and behavioral analyses to investigate possible alterations in corticostriatal function in FGF2 -/- mice. RESULTS: We found that FGF2 deficiency leads to decreased expression of presynaptic markers of integrity for glutamatergic fibers in the striatum, namely the membrane excitatory amino acid transporter 3 (EAAT3) and the vesicular glutamate transporter 1 (VGLUT1). The reduction of corticostriatal glutamatergic function in FGF2 -/- mice is associated with enhanced locomotor activity in a novel environment and increased responsiveness to dopaminergic drugs, such as cocaine or amphetamine. The behavioral alterations of FGF2 -/- can be normalized by injection of a low dose of the dopaminergic agonist apomorphine (.1 mg/kg) that reduces dopamine release by acting on presynaptic receptors. CONCLUSIONS: Our data demonstrate that FGF2 -/- mice have an increased tone and responsiveness of the dopaminergic system and suggest that these animals might represent a model to study disorders that are characterized by an imbalance between glutamatergic and dopaminergic neurotransmission.
Subject(s)
Dopamine/metabolism , Fibroblast Growth Factor 2/physiology , Frontal Lobe/metabolism , Motor Activity/physiology , Neostriatum/metabolism , Neural Pathways/metabolism , Actins/genetics , Actins/metabolism , Analysis of Variance , Animals , Apomorphine/pharmacology , Cocaine/pharmacology , Dextroamphetamine/pharmacology , Dopamine Agents/pharmacology , Excitatory Amino Acid Transporter 3/genetics , Excitatory Amino Acid Transporter 3/metabolism , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Fibroblast Growth Factor 2/deficiency , Frontal Lobe/cytology , Frontal Lobe/drug effects , Glutamic Acid/metabolism , Hyperkinesis/metabolism , Mice , Mice, Knockout , Motor Activity/drug effects , Neostriatum/drug effects , Nerve Fibers/metabolism , Presynaptic Terminals/drug effects , Presynaptic Terminals/metabolism , RNA, Messenger/analysis , Synaptic Transmission/physiology , Vesicular Glutamate Transport Protein 1/genetics , Vesicular Glutamate Transport Protein 1/metabolismABSTRACT
Several studies have shown that behavioral hyperactivity induced by psychomotor stimulants is prevented by ginseng saponins. In an attempt to investigate whether the effect of ginseng saponins is through their inhibitory action on the enhanced dopaminergic transmission by psychomotor stimulants, we examined the effects of ginseng total saponin (GTS) presynaptically on nicotine-induced dopamine (DA) release in the striatum of freely moving rats using in vivo microdialysis technique and postsynaptically on the in vitro and in vivo binding of [3H]raclopride to DA D2 receptors. Also, we examined the effects of GTS on nicotine-induced locomotor hyperactivity and on nicotine-induced Fos protein expression in the nucleus accumbens and striatum. Systemic pretreatment with GTS (100 and 400 mg/kg, intraperitoneally (i.p.)) resulted in a dose-dependent inhibition of locomotor hyperactivity induced by nicotine. GTS decreased nicotine-induced DA release in the striatum in a dose-dependent manner. However, GTS had no effects on resting levels of locomotor activity and extracellular DA in the striatum. GTS inhibited the in vitro binding of [3H]raclopride to rat striatal membranes with an IC50 of 5.14+/-1.09 microM. High doses of GTS (400 and 800 mg/kg, i.p.) resulted in decreases in the in vivo binding of [3H]raclopride in the striatum. GTS decreased nicotine-induced Fos protein expression in the nucleus accumbens and striatum, reflecting the inhibition by GTS of nicotine-induced enhancement of dopaminergic transmission. The results of the present study suggest that GTS acts not only on dopaminergic neurons directly or indirectly to prevent nicotine-induced DA release but also postsynaptically by binding to DA D2 receptors. This may explain the blocking effect of GTS on behavioral activation induced by nicotine and conceivably by other psychostimulants. Our data raise the possibility that GTS, by attenuating nicotine-induced enhancement of dopaminergic transmission, may prove to be a useful therapeutic agent for nicotine addiction and warrant further investigation on its effect on nicotine's rewarding property.
Subject(s)
Dopamine/physiology , Hyperkinesis/metabolism , Nicotine/toxicity , Panax , Receptors, Dopamine/metabolism , Saponins/metabolism , Animals , Dopamine/metabolism , Dose-Response Relationship, Drug , Hyperkinesis/chemically induced , Hyperkinesis/prevention & control , Male , Mice , Mice, Inbred ICR , Protein Binding/drug effects , Protein Binding/physiology , Rats , Rats, Sprague-Dawley , Saponins/pharmacology , Synaptic Transmission/drug effects , Synaptic Transmission/physiologyABSTRACT
Activated lipid peroxidation observed in brain homogenates in experimental choreoid hyperkinesis and bemegride epilepsy can be arrested by antioxidant pretreatment. The same is true for parkinsonian and "malignant locomotion" syndromes provoked by intrastriatal pro-oxidant (oxidized oleinic acid) microinjection and systemic administration of haloperidol. Experimental therapy of choreoid hyperkinesis with GABA-positive and dopamine-blocking drugs alone proved ineffective. The effect was achieved at combined application of antioxidant and GABA-positive drugs.